It is related to farnesylthiosalicylic acid (Salirasib, FTA) loaded PLGA nanoparticles functionalized with lipid/cationic lipid-PEG (hybrid), which can cross the BBB in effective concentration. The formulations can be administered intravenously or intratumorally.